Homology Medicines Alpha and Beta Analysis
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Homology Medicines. It also helps investors analyze the systematic and unsystematic risks associated with investing in Homology Medicines over a specified time horizon. Remember, high Homology Medicines' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Homology Medicines' market risk premium analysis include:
Beta 0.0617 | Alpha 0.14 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Homology |
Homology Medicines Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Homology Medicines market risk premium is the additional return an investor will receive from holding Homology Medicines long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Homology Medicines. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Homology Medicines' performance over market.| α | 0.14 | β | 0.06 |
Homology Medicines Fundamentals Vs Peers
Comparing Homology Medicines' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Homology Medicines' direct or indirect competition across all of the common fundamentals between Homology Medicines and the related equities. This way, we can detect undervalued stocks with similar characteristics as Homology Medicines or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Homology Medicines' fundamental indicators could also be used in its relative valuation, which is a method of valuing Homology Medicines by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Homology Medicines to competition |
| Fundamentals | Homology Medicines | Peer Average |
| Return On Equity | -0.9 | -0.31 |
| Return On Asset | -0.36 | -0.14 |
| Operating Margin | (78.85) % | (5.51) % |
| Current Valuation | (27 M) | 16.62 B |
| Shares Outstanding | 3.23 M | 571.82 M |
| Shares Owned By Insiders | 9.20 % | 10.09 % |
| Shares Owned By Institutions | 46.75 % | 39.21 % |
Homology Medicines Opportunities
Homology Medicines Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Screening hydrogels for antifibrotic properties by implanting ... - Nature.com | 04/27/2023 |
2 | GenScript Doubles cGMP sgRNA and Non-Viral DNA Payload Manufacturing Capacity - Yahoo Finance | 07/06/2023 |
About Homology Medicines Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Homology or other delisted stocks. Alpha measures the amount that position in Homology Medicines has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Homology Medicines Upcoming Company Events
As portrayed in its financial statements, the presentation of Homology Medicines' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Homology Medicines' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Homology Medicines' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Homology Medicines. Please utilize our Beneish M Score to check the likelihood of Homology Medicines' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Homology Medicines
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |